Other Trials

Other

Growth Regulation in Fetuses with Cardiac Malformations

Pl: Andrea Hinton MD
Contact Person: Ganga Devaiah MS, 513 862 2341 or Ganga_devaiah@trihealth.com; or Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com

Inclusion Criteria:  

• Fetal diagnosis of Hypoplastic Left Heart Syndrome
• Clinically obtained amniocentesis

Exclusion Criteria:

• Genetic syndrome diagnosis (e.g. Turner Syndrome)
• Mother with a condition that potentially results in growth abnormalities (e.g. preeclampsia, diabetes, abnormal quad screen).
• Advanced maternal age >35 years
• Mothers less than 18 years of age

Randomized Multi-Center of Antenatal Treatment of Alloimmune Thrombocytopenia

PI: William Polzin MD
Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com

Inclusion Criteria: Very High Risk Group

• Pregnant women are eligible for inclusion into the very high risk group if they:
  • Are PLA-1 negative and have known platelet incompatibility with their fetus
  • Have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation
  • Are less than study 19 weeks gestation
   

Exclusion Criteria: Very High Risk Group

• Women are not eligible for inclusion into the very high risk group if they:
  • Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
  • Are greater than 19 weeks gestation
   

Inclusion Criteria: High Risk Group

• Pregnant women are eligible for inclusion into the high risk group if they:
  • Are PLA-1 negative and have known platelet incompatibility with the fetus
  • Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
  • Are between 12-30 weeks of gestation
   

Exclusion Criteria: High Risk Group

• Women are not eligible for inclusion into the high risk group if they:
  • Have had a previous child who suffered an antenatal hemorrhage prior 28 weeks gestation
  • Are greater than 30 weeks gestation
   

Inclusion Criteria: Standard Risk Group

• Pregnant women are eligible for inclusion into the standard risk group if they:
  • Are PLA_1 negative and have known platelet incompatibility with the fetus
  • Have not had a previous child who suffered an antenatal hemorrhage
  • Are between 20-30 weeks of gestation
  ;

Exclusion Criteria: Standard Risk Group

• Women are not eligible for inclusion into the standard risk group if they:
  • Have had a previous child who suffered an antenatal hemorrhage
  • Are greater than 30 weeks gestation 
   

Novel Biomarkers in Amniotic Fluid to Predict Fetal Lung Maturity and Clinical Respiratory Outcomes

PI: Beena Kamath MD
Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com
Inclusion Criteria:

• 18 years of age or older
• Pregnant between 34 to < 39 weeks gestation
• Amniocenteses

A Phase III, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of LIBIGEL for the Treatment of Hypoactive Sexual Desire (HSDD) in Postmenopausal Women

PI: Rachel Pauls MD
Contact Person: Vivian Ghodsi RN CCRC, 513 463 4308 or Vivian_Ghodsi@TriHealth.com

• Inclusion Criteria: Closed to enrollment. Follow-up only
• Exclusion Criteria: Closed to enrollment. Follow-up only

Closure of Pfannenstiel Skin Incisions after Cesarean Delivery:  A comparison of Metallic Staples versus Absorbable Staples

PI: Catherine Feese MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or  Michaela_Eschenbacher@TriHealth.com 

• Inclusion Criteria: Closed to enrollment. Follow-up only
• Exclusion Criteria: Closed to enrollment. Follow-up only

Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance

PI: Donna Lambers MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com

• Inclusion Criteria: Closed to enrollment. Follow-up only
• Exclusion Criteria: Closed to enrollment. Follow-up only

Assessment of Pain and Embarrassment with Urodynamic Testing in Women: A Prospective Study

PI: Rachel Pauls MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com      

• Inclusion Criteria: Closed to enrollment. Follow-up only
• Exclusion Criteria: Closed to enrollment. Follow-up only

Mechanisms of Correction of Fetal Growth Restriction

PI: Mounira Habli MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com

• Inclusion: All healthy pregnant females between 19-45 scheduled for a csection at >37 weeks between Monday and Friday
• Exclusion: All preterm scheduled csections, medically complicated patients, and patients who refuse participation